Please Wait
Applying Filters...
menu
    • menu
    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Onvansertib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Cardiff teases onvansertib efficacy in colorectal cancer
    Cardiff teases onvansertib efficacy in colorectal cancer

    01 Mar 2024

    // Ayisha Sharma ENDPTS

    https://endpts.com/cardiff-teases-plk1-inhibitor-efficacy-in-colorectal-cancer-ahead-of-first-line-readout/

    Ayisha Sharma ENDPTS
    01 Mar 2024
    Share Share
    Cardiff Oncology Announces Plans for a Randomized Trial in mCRC
    Cardiff Oncology Announces Plans for a Randomized Trial in mCRC

    12 Sep 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/cardiff-oncology-announces-plans-for-a-randomized-trial-in-metastatic-colorectal-cancer-mcrc-durability-of-responses-in-ongoing-phase-1b2-trial-in-mcrc-and-additional-business-updates-301622266.html

    PRNEWSWIRE
    12 Sep 2022
    Share Share
    Cardiff Oncology Announces Data from Program in KRAS-mutated mCRC
    Cardiff Oncology Announces Data from Program in KRAS-mutated mCRC

    11 Sep 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/cardiff-oncology-announces-new-preclinical-and-clinical-data-from-program-in-kras-mutated-metastatic-colorectal-cancer-mcrc-at-the-esmo-congress-2022-301621536.html

    PRNEWSWIRE
    11 Sep 2022
    Share Share
    Cardiff Oncology Shows Data Showing Combo of PARP Inhibition with Onvansertib
    Cardiff Oncology Shows Data Showing Combo of PARP Inhibition with Onvansertib

    08 Apr 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/cardiff-oncology-announces-data-showing-the-combination-of-parp-inhibition-with-onvansertib-overcomes-parp-inhibitor-resistance-in-brca1-mutant-and-wildtype-patient-derived-xenograft-ovarian-cancer-models-301520694.html

    PRNEWSWIRE
    08 Apr 2022
    Share Share
    Cardiff Oncology Announces New Data from Lead Clinical Program in KRAS-mutated Metastatic Colorectal Cancer Showing Robust Objective Response Rate and Progression Free Survival
    Cardiff Oncology Announces New Data from Lead Clinical Program in KRAS-mutated Metastatic Colorectal Cancer Showing Robust Objective Response Rate and Progression Free Survival

    18 Jan 2022

    // PRESS RELEASE

    https://cardiffoncology.investorroom.com/2022-01-18-Cardiff-Oncology-Announces-New-Data-from-Lead-Clinical-Program-in-KRAS-mutated-Metastatic-Colorectal-Cancer-Showing-Robust-Objective-Response-Rate-and-Progression-Free-Survival

    PRESS RELEASE
    18 Jan 2022
    Share Share
    Pfizer invests $15M in Cardiff to bankroll Amgen KRAS challenger
    Pfizer invests $15M in Cardiff to bankroll Amgen KRAS challenger

    19 Nov 2021

    // PRECISIONONCOLOGYNEWS

    https://www.precisiononcologynews.com/business-news/pfizer-makes-15m-equity-investment-cardiff-oncology#.YZdW-WBBzIU

    PRECISIONONCOLOGYNEWS
    19 Nov 2021
    Share Share